Doryan Masmoudi,Catherine Alix-Panabières,Zahra Eslami-S
Doryan Masmoudi
Integrating immunopeptidomics with liquid biopsy could expand the scope of precision oncology, providing dynamic, patient-specific insights into antigen presentation for developing and monitoring personalized immunotherapies in a minimally invasive manner.
Selective Recognition of Tumor-Derived EVs by EpCAM-Imprinted Polymers for Proteomic Biomarker Discovery [0.03%]
Wenjing Yu,Fengxiang Lou,Luxi Chen et al.
Wenjing Yu et al.
EpCAM, a key biomarker for epithelial tumors, is overexpressed in multiple cancers and enriched on tumor-derived extracellular vesicles (EVs), positioning it as a promising liquid biopsy target.
Generic Protocols for the Analytical Validation of Next-Generation Sequencing-Based Circulating Tumor DNA Assays, Version 2.0 [0.03%]
Angela Silvestro,Jonathan Baden,Kevin Billings et al.
Angela Silvestro et al.
As a result, an increasing number of diagnostic developers are pursuing liquid biopsy assays using next-generation sequencing (NGS) to detect ctDNA.
Emeka Eze Joshua Iweala,Chukwuemeka Pius Nwokoro
Emeka Eze Joshua Iweala
The combined use of immunotherapy with personalized medicine along with liquid biopsy technologies will improve therapeutic effects by enabling real-time tracking of disease evolution and treatment response.
From escort to target, the multidimensional roles and prospects of platelets in tumor immune checkpoint inhibitor therapy [0.03%]
Jiayu Xiao,Huaru Wang,Xinyue Liu et al.
Jiayu Xiao et al.
Of note, platelet-associated immune checkpoint molecules (e.g., PD-L1) have shown great promise as liquid biopsy markers for patient stratification and real-time immunomonitoring.
A comprehensive toolkit for analyzing cell-free DNA genomic sequencing data in liquid biopsy [0.03%]
针对液体活检中游离DNA基因组测序数据的全面分析工具包
Junpeng Zhou,Keyao Zhu,Xiaoqian Huang et al.
Junpeng Zhou et al.
By standardizing and accelerating cfDNA analysis, cfDNAanalyzer enables reproducible biomarker discovery and advances translational liquid biopsy research.
Early detection and subtyping of gastric cancer: A cell-free DNA fragmentome-based liquid biopsy method [0.03%]
基于游离DNA片段组的胃癌早期检测与分型液体活检方法
Yongyi Chen,Haiqi Liao,Yuzhi Liu et al.
Yongyi Chen et al.
Cell-free DNA (cfDNA) in plasma provides attractive opportunities for early cancer diagnosis. This study aimed to establish gastric cancer (GC) artificial intelligence algorithms (GC-AIAs) based on cfDNA fragmentome for GC's early detection...
Research progress of surface-enhanced Raman scattering technology in tumor liquid biopsy [0.03%]
表面增强拉曼散射技术在肿瘤液体活检中研究进展
Yuanchao Cao,Dingyu Rao,Defa Huang et al.
Yuanchao Cao et al.
This review systematically summarizes the recent advances of SERS in detecting key liquid biopsy biomarkers (exosomes, CTCs, ctDNA), critically analyzes its advantages in sensitivity and multiplexing, and discusses the main challenges for clinical translation, including signal interference in complex
Dynamic changes in liquid biopsy markers during OSCC treatment: A longitudinal study [0.03%]
一项关于口腔鳞癌治疗过程中液体活检标志物纵向变化的研究
Amit Kumar Joseph,Gaurav Khatri,Surapaneni Keerthi Sai et al.
Amit Kumar Joseph et al.
Therefore, it is of interest to investigate the dynamic changes in liquid biopsy markers circulating tumor deoxyribonucleic acid (ctDNA), circulating tumor cells (CTCs), exosomes and micro ribonucleic acids (microRNA) during OSCC treatment.
Type-specific detection and quantification of circulating tumor HPV DNA by digital PCR in surgically resected cervical cancer [0.03%]
手术切除宫颈癌患者循环肿瘤HPVDNA的类型特异性检测与定量研究数字PCR法
Asami Matsunaga,Miho Ogawa,Akiko Kunita et al.
Asami Matsunaga et al.
significantly higher in cases with lymphovascular invasion (p=0.034) and lymph node metastasis (p=0.010), but were not correlated with tumor size, stage, or histologic type. ctHPV DNA was more consistently detectable than PIK3CA hotspot mutations in plasma, supporting its robustness as a biomarker in liquid...biopsy settings.
耗时 0.14116 秒，为您在
49818390
条记录里面共找到 7078 篇文章 [XML]